Payment overview · 2025
General Payments
$117.85
6 reported records · 3 companies
Healthcare provider profile · identity verified
Christopher George Fleissner, DO
Allopathic & Osteopathic Physicians|Family Medicine · PITTSBURGH, PA · NPI 1588827828
Verified facts
What the public records show
CMS Open Payments records show Christopher George Fleissner, DO received $117.85 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 61.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.89 | 61.9% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $26.57 | 22.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.39 | 15.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.85 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $26.57 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 223 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
223 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
223 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 673 | 188 |
| Lisinopril | Lisinopril | 504 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 493 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 115 |
| Omeprazole | Omeprazole | 363 | 83 |
| Gabapentin | Gabapentin | 334 | 75 |
| Metformin Hcl | Metformin Hcl | 290 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 288 | 74 |
| Furosemide | Furosemide | 241 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 53 |
| Eliquis | Apixaban | 223 | 33 |
| Ozempic | Semaglutide | 223 | 35 |
| Losartan Potassium | Losartan Potassium | 200 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 43 |
| Simvastatin | Simvastatin | 158 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 47 |
| Trazodone Hcl | Trazodone Hcl | 146 | 31 |
| Atenolol | Atenolol | 131 | 36 |
| Ibuprofen | Ibuprofen | 121 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 19 |
| Alendronate Sodium | Alendronate Sodium | 100 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 16 |
| Famotidine | Famotidine | 89 | 30 |
| Meloxicam | Meloxicam | 88 | 24 |
| Montelukast Sodium | Montelukast Sodium | 85 | 25 |
| Celecoxib | Celecoxib | 82 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 20 |
| Carvedilol | Carvedilol | 77 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 17 |
| Buspirone Hcl | Buspirone Hcl | 73 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 18 |
| Sertraline Hcl | Sertraline Hcl | 71 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 27 |
| Allopurinol | Allopurinol | 65 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | suppressed |
| Potassium Chloride | Potassium Chloride | 65 | 22 |
| Trulicity | Dulaglutide | 65 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 15 |
| Clonazepam | Clonazepam | 63 | 12 |
| Valsartan | Valsartan | 63 | 24 |
| Naproxen | Naproxen | 60 | 18 |
| Topiramate | Topiramate | 60 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 53 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 17 |
| Alprazolam | Alprazolam | 51 | 18 |
| Jardiance | Empagliflozin | 51 | 12 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | 12 |
| Spironolactone | Spironolactone | 46 | 11 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Azithromycin | Azithromycin | 44 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 18 |
| Xarelto | Rivaroxaban | 43 | 12 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 12 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 14 |
| Tramadol Hcl | Tramadol Hcl | 39 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 17 |
| Finasteride | Finasteride | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Prednisone | Prednisone | 36 | 32 |
| Lorazepam | Lorazepam | 35 | 14 |
| Colchicine | Colchicine | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ibu | Ibuprofen | 25 | 11 |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Nystatin | Nystatin | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.85 · 6 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, NEXPLANON, Ozempic, PREVNAR 20, Rybelsus, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error